2 Monster Young Biotech Stocks to Add to Your Watchlist

Monster biotech stocks are few and far between. Drug development is a high risk playing field, and many companies struggle to replicate their successes even if they get a single product approved for commercialization. Other companies seem to have highly promising projects, but never manage to deliver on their promises. For investors, it's quite challenging to identify the biotech stocks of the future when they're in the early stages.

The two companies I'll be discussing today are relatively young businesses. But they have deeply compelling projects that aim to cure or fully mitigate a handful of different medical conditions that were once considered intractable. Both have demonstrated excellent progress so far, not to mention financial strength. It'll take them some time to proceed with clinical trials and eventually pull through for shareholders, but when they do, the rewards could be enormous.

Image source: Getty Images.

Source Fool.com